Table 3 Changes in annual DDD and drug expenditures (year-to-year rates of increase in parenthesis)
From: Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea
| Â | 2005 | 2006 | 2007 | 2008 | 2009 | 2005-2009 | Annual | |
|---|---|---|---|---|---|---|---|---|
Statin | Sum of DDD | 128,545,620 | 193,278,414 (50.36%) | 274,288,699 (41.91%) | 344,893,058 (25.74%) | 445,426,185 | 246.51% | 36.44% |
Drug expenditure per DDD (unit: won) | 1,506 | 1,392 | 1,276 | 1,185 | 1,085 | −27.95% | −7.87% | |
Total statin expenditure (unit: million won) | 193.6 | 269.0 (38.96%) | 350.0 (30.12%) | 408.8 (16.82%) | 483.1 (18.16%) | 149.57% | 25.69% | |
All Lipid-lowering drugs | Sum of DDD | 154,832,421 | 224,516,146 (45.01%) | 314,095,889 (39.90%) | 392,818,319 (25.06%) | 506,311,055 (28.89%) | 227.01% | 34.47% |
Drug expenditure per DDD (unit: won) | 1,349 | 1,285 | 1,206 | 1,136 | 1,052 | −22.02% | −6.03% | |
| Â | Total expenditure (unit: million won) | 208.9 | 288.5 (38.09%) | 378.7 (31.27%) | 446.1 (17.82%) | 532.5 (19.36%) | 154.93% | 26.36% |